Lumos Diagnostics Holdings Limited (ASX:LDX)

Market Cap	139.62M
Revenue (ttm)	18.91M
Net Income (ttm)	-10.96M
Shares Out	775.66M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,740,839
Average Volume	6,134,284
Open	0.1600
Previous Close	0.1650
Day's Range	0.1550 - 0.1900
52-Week Range	0.0190 - 0.1900
Beta	0.61
RSI	76.67
Earnings Date	Nov 26, 2025

About ASX:LDX

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. Its products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also offers assay development and manufacturing services for point-of-care tests and proprietary digital reader platf...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LDX

Financial Performance

In 2025, ASX:LDX's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.

Financial numbers in USD